世界の副腎白質ジストロフィー薬市場2020-2025:ホルモン補充、移植、その他

LP Informationが発行した調査報告書(LPI20JN00121)
◆英語タイトル:Global Adrenoleukodystrophy Drugs Market Growth 2020-2025
◆商品コード:LPI20JN00121
◆発行会社(リサーチ会社):LP Information
◆発行日:2020年6月
◆ページ数:135
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single UserUSD3,660 ⇒換算¥402,600見積依頼/購入/質問フォーム
Multi UserUSD5,490 ⇒換算¥603,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

「副腎白質ジストロフィー薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、ホルモン補充、移植、その他など、用途別には、小児大脳ALD、アドレノミロニューロパチー(AMN)、アディソンのみ、その他などに区分してまとめた調査レポートです。副腎白質ジストロフィー薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・副腎白質ジストロフィー薬の世界市場概要(サマリー)
・副腎白質ジストロフィー薬の企業別販売量・売上
・副腎白質ジストロフィー薬の企業別市場シェア
・副腎白質ジストロフィー薬の世界市場規模 2015年-2020年:種類別(ホルモン補充、移植、その他)
・副腎白質ジストロフィー薬の世界市場規模 2015年-2020年:用途別(小児大脳ALD、アドレノミロニューロパチー(AMN)、アディソンのみ、その他)
・副腎白質ジストロフィー薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・副腎白質ジストロフィー薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・副腎白質ジストロフィー薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・副腎白質ジストロフィー薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・副腎白質ジストロフィー薬市場の成長要因・課題・動向
・副腎白質ジストロフィー薬の世界市場予測 2021年-2025年
・副腎白質ジストロフィー薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・副腎白質ジストロフィー薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・副腎白質ジストロフィー薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・副腎白質ジストロフィー薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・副腎白質ジストロフィー薬の世界市場予測:種類別(ホルモン補充、移植、その他)
・副腎白質ジストロフィー薬の世界市場予測:用途別(小児大脳ALD、アドレノミロニューロパチー(AMN)、アディソンのみ、その他)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Adrenoleukodystrophy Drugs market will register a 16.5% CAGR in terms of revenue, the global market size will reach $ 453.1 million by 2025, from $ 246 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Adrenoleukodystrophy Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Adrenoleukodystrophy Drugs market by type, application, key manufacturers and key regions and countries.

This study considers the Adrenoleukodystrophy Drugs value and volume generated from the sales of the following segments:

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Hormone Replacement
Transplant
Others

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bluebird Bio Inc
NeuroVia, Inc.
Minoryx
MedDay Pharmaceuticals
Orpheris, Inc.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Adrenoleukodystrophy Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Adrenoleukodystrophy Drugs market by identifying its various subsegments.
Focuses on the key global Adrenoleukodystrophy Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Adrenoleukodystrophy Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Adrenoleukodystrophy Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Adrenoleukodystrophy Drugs Consumption 2015-2025
2.1.2 Adrenoleukodystrophy Drugs Consumption CAGR by Region
2.2 Adrenoleukodystrophy Drugs Segment by Type
2.2.1 Hormone Replacement
2.2.2 Transplant
2.2.3 Others
2.3 Adrenoleukodystrophy Drugs Consumption by Type
2.3.1 Global Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Adrenoleukodystrophy Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Adrenoleukodystrophy Drugs Sale Price by Type (2015-2020)
2.4 Adrenoleukodystrophy Drugs Segment by Application
2.4.1 Childhood Cerebral ALD
2.4.2 Adrenomyeloneuropathy (AMN)
2.4.3 Addison-only
2.4.4 Others
2.5 Adrenoleukodystrophy Drugs Consumption by Application
2.5.1 Global Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Adrenoleukodystrophy Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Adrenoleukodystrophy Drugs Sale Price by Type (2015-2020)

3 Global Adrenoleukodystrophy Drugs by Company
3.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Company
3.1.1 Global Adrenoleukodystrophy Drugs Sales by Company (2018-2020)
3.1.2 Global Adrenoleukodystrophy Drugs Sales Market Share by Company (2018-2020)
3.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Company
3.2.1 Global Adrenoleukodystrophy Drugs Revenue by Company (2018-2020)
3.2.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Adrenoleukodystrophy Drugs Sale Price by Company
3.4 Global Adrenoleukodystrophy Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Adrenoleukodystrophy Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Adrenoleukodystrophy Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Adrenoleukodystrophy Drugs by Regions
4.1 Adrenoleukodystrophy Drugs by Regions
4.2 Americas Adrenoleukodystrophy Drugs Consumption Growth
4.3 APAC Adrenoleukodystrophy Drugs Consumption Growth
4.4 Europe Adrenoleukodystrophy Drugs Consumption Growth
4.5 Middle East & Africa Adrenoleukodystrophy Drugs Consumption Growth

5 Americas
5.1 Americas Adrenoleukodystrophy Drugs Consumption by Countries
5.1.1 Americas Adrenoleukodystrophy Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Adrenoleukodystrophy Drugs Value by Countries (2015-2020)
5.2 Americas Adrenoleukodystrophy Drugs Consumption by Type
5.3 Americas Adrenoleukodystrophy Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Adrenoleukodystrophy Drugs Consumption by Regions
6.1.1 APAC Adrenoleukodystrophy Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Adrenoleukodystrophy Drugs Value by Regions (2015-2020)
6.2 APAC Adrenoleukodystrophy Drugs Consumption by Type
6.3 APAC Adrenoleukodystrophy Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Adrenoleukodystrophy Drugs by Countries
7.1.1 Europe Adrenoleukodystrophy Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Adrenoleukodystrophy Drugs Value by Countries (2015-2020)
7.2 Europe Adrenoleukodystrophy Drugs Consumption by Type
7.3 Europe Adrenoleukodystrophy Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Adrenoleukodystrophy Drugs by Countries
8.1.1 Middle East & Africa Adrenoleukodystrophy Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Adrenoleukodystrophy Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Adrenoleukodystrophy Drugs Consumption by Type
8.3 Middle East & Africa Adrenoleukodystrophy Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Adrenoleukodystrophy Drugs Distributors
10.3 Adrenoleukodystrophy Drugs Customer

11 Global Adrenoleukodystrophy Drugs Market Forecast
11.1 Global Adrenoleukodystrophy Drugs Consumption Forecast (2021-2025)
11.2 Global Adrenoleukodystrophy Drugs Forecast by Regions
11.2.1 Global Adrenoleukodystrophy Drugs Forecast by Regions (2021-2025)
11.2.2 Global Adrenoleukodystrophy Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Adrenoleukodystrophy Drugs Forecast by Type
11.8 Global Adrenoleukodystrophy Drugs Forecast by Application

12 Key Players Analysis
12.1 Bluebird Bio Inc
12.1.1 Company Information
12.1.2 Adrenoleukodystrophy Drugs Product Offered
12.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Bluebird Bio Inc Latest Developments
12.2 NeuroVia, Inc.
12.2.1 Company Information
12.2.2 Adrenoleukodystrophy Drugs Product Offered
12.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 NeuroVia, Inc. Latest Developments
12.3 Minoryx
12.3.1 Company Information
12.3.2 Adrenoleukodystrophy Drugs Product Offered
12.3.3 Minoryx Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Minoryx Latest Developments
12.4 MedDay Pharmaceuticals
12.4.1 Company Information
12.4.2 Adrenoleukodystrophy Drugs Product Offered
12.4.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 MedDay Pharmaceuticals Latest Developments
12.5 Orpheris, Inc.
12.5.1 Company Information
12.5.2 Adrenoleukodystrophy Drugs Product Offered
12.5.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Orpheris, Inc. Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Adrenoleukodystrophy Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Hormone Replacement
Table 5. Major Players of Transplant
Table 6. Major Players of Others
Table 7. Global Consumption Sales by Type (2015-2020)
Table 8. Global Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
Table 9. Global Adrenoleukodystrophy Drugs Revenue by Type (2015-2020) ($ million)
Table 10. Global Adrenoleukodystrophy Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 11. Global Adrenoleukodystrophy Drugs Sale Price by Type (2015-2020)
Table 12. Global Consumption Sales by Application (2015-2020)
Table 13. Global Adrenoleukodystrophy Drugs Consumption Market Share by Application (2015-2020)
Table 14. Global Adrenoleukodystrophy Drugs Value by Application (2015-2020)
Table 15. Global Adrenoleukodystrophy Drugs Value Market Share by Application (2015-2020)
Table 16. Global Adrenoleukodystrophy Drugs Sale Price by Application (2015-2020)
Table 17. Global Adrenoleukodystrophy Drugs Sales by Company (2017-2019) (K Units)
Table 18. Global Adrenoleukodystrophy Drugs Sales Market Share by Company (2017-2019)
Table 19. Global Adrenoleukodystrophy Drugs Revenue by Company (2017-2019) ($ Millions)
Table 20. Global Adrenoleukodystrophy Drugs Revenue Market Share by Company (2017-2019)
Table 21. Global Adrenoleukodystrophy Drugs Sale Price by Company (2017-2019)
Table 22. Global Adrenoleukodystrophy Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 23. Players Adrenoleukodystrophy Drugs Products Offered
Table 24. Adrenoleukodystrophy Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 25. Global Adrenoleukodystrophy Drugs Consumption by Regions 2015-2020 (K Units)
Table 26. Global Adrenoleukodystrophy Drugs Consumption Market Share by Regions 2015-2020
Table 27. Global Adrenoleukodystrophy Drugs Value by Regions 2015-2020 ($ Millions)
Table 28. Global Adrenoleukodystrophy Drugs Value Market Share by Regions 2015-2020
Table 29. Americas Adrenoleukodystrophy Drugs Consumption by Countries (2015-2020) (K Units)
Table 30. Americas Adrenoleukodystrophy Drugs Consumption Market Share by Countries (2015-2020)
Table 31. Americas Adrenoleukodystrophy Drugs Value by Countries (2015-2020) ($ Millions)
Table 32. Americas Adrenoleukodystrophy Drugs Value Market Share by Countries (2015-2020)
Table 33. Americas Adrenoleukodystrophy Drugs Consumption by Type (2015-2020) (K Units)
Table 34. Americas Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
Table 35. Americas Adrenoleukodystrophy Drugs Consumption by Application (2015-2020) (K Units)
Table 36. Americas Adrenoleukodystrophy Drugs Consumption Market Share by Application (2015-2020)
Table 37. APAC Adrenoleukodystrophy Drugs Consumption by Countries (2015-2020) (K Units)
Table 38. APAC Adrenoleukodystrophy Drugs Consumption Market Share by Countries (2015-2020)
Table 39. APAC Adrenoleukodystrophy Drugs Value by Regions (2015-2020) ($ Millions)
Table 40. APAC Adrenoleukodystrophy Drugs Value Market Share by Regions (2015-2020)
Table 41. APAC Adrenoleukodystrophy Drugs Consumption by Type (2015-2020) (K Units)
Table 42. APAC Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
Table 43. APAC Adrenoleukodystrophy Drugs Consumption by Application (2015-2020) (K Units)
Table 44. APAC Adrenoleukodystrophy Drugs Consumption Market Share by Application (2015-2020)
Table 45. Europe Adrenoleukodystrophy Drugs Consumption by Countries (2015-2020) (K Units)
Table 46. Europe Adrenoleukodystrophy Drugs Consumption Market Share by Countries (2015-2020)
Table 47. Europe Adrenoleukodystrophy Drugs Value by Countries (2015-2020) ($ Millions)
Table 48. Europe Adrenoleukodystrophy Drugs Value Market Share by Countries (2015-2020)
Table 49. Europe Adrenoleukodystrophy Drugs Consumption by Type (2015-2020) (K Units)
Table 50. Europe Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
Table 51. Europe Adrenoleukodystrophy Drugs Consumption by Application (2015-2020) (K Units)
Table 52. Europe Adrenoleukodystrophy Drugs Consumption Market Share by Application (2015-2020)
Table 53. Middle East & Africa Adrenoleukodystrophy Drugs Consumption by Countries (2015-2020) (K Units)
Table 54. Middle East & Africa Adrenoleukodystrophy Drugs Consumption Market Share by Countries (2015-2020)
Table 55. Middle East & Africa Adrenoleukodystrophy Drugs Value by Countries (2015-2020) ($ Millions)
Table 56. Middle East & Africa Adrenoleukodystrophy Drugs Value Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Adrenoleukodystrophy Drugs Consumption by Type (2015-2020) (K Units)
Table 58. Middle East & Africa Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
Table 59. Middle East & Africa Adrenoleukodystrophy Drugs Consumption by Application (2015-2020) (K Units)
Table 60. Middle East & Africa Adrenoleukodystrophy Drugs Consumption Market Share by Application (2015-2020)
Table 61. Adrenoleukodystrophy Drugs Distributors List
Table 62. Adrenoleukodystrophy Drugs Customer List
Table 63. Global Adrenoleukodystrophy Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 64. Global Adrenoleukodystrophy Drugs Consumption Market Forecast by Regions
Table 65. Global Adrenoleukodystrophy Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 66. Global Adrenoleukodystrophy Drugs Value Market Share Forecast by Regions
Table 67. Global Adrenoleukodystrophy Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 68. Global Adrenoleukodystrophy Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 69. Global Adrenoleukodystrophy Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 70. Global Adrenoleukodystrophy Drugs Value Market Share Forecast by Type (2021-2025)
Table 71. Global Adrenoleukodystrophy Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 72. Global Adrenoleukodystrophy Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 73. Global Adrenoleukodystrophy Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 74. Global Adrenoleukodystrophy Drugs Value Market Share Forecast by Application (2021-2025)
Table 75. Bluebird Bio Inc Product Offered
Table 76. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 77. Bluebird Bio Inc Main Business
Table 78. Bluebird Bio Inc Latest Developments
Table 79. Bluebird Bio Inc Basic Information, Company Total Revenue (in $ million), Adrenoleukodystrophy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. NeuroVia, Inc. Product Offered
Table 81. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 82. NeuroVia, Inc. Main Business
Table 83. NeuroVia, Inc. Latest Developments
Table 84. NeuroVia, Inc. Basic Information, Company Total Revenue (in $ million), Adrenoleukodystrophy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Minoryx Product Offered
Table 86. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 87. Minoryx Main Business
Table 88. Minoryx Latest Developments
Table 89. Minoryx Basic Information, Company Total Revenue (in $ million), Adrenoleukodystrophy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. MedDay Pharmaceuticals Product Offered
Table 91. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 92. MedDay Pharmaceuticals Main Business
Table 93. MedDay Pharmaceuticals Latest Developments
Table 94. MedDay Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Adrenoleukodystrophy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Orpheris, Inc. Product Offered
Table 96. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 97. Orpheris, Inc. Main Business
Table 98. Orpheris, Inc. Latest Developments
Table 99. Orpheris, Inc. Basic Information, Company Total Revenue (in $ million), Adrenoleukodystrophy Drugs Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Adrenoleukodystrophy Drugs
Figure 2. Adrenoleukodystrophy Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Adrenoleukodystrophy Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Adrenoleukodystrophy Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Hormone Replacement
Figure 7. Product Picture of Transplant
Figure 8. Product Picture of Others
Figure 9. Global Adrenoleukodystrophy Drugs Consumption Market Share by Type (2015-2020)
Figure 10. Global Adrenoleukodystrophy Drugs Value Market Share by Type (2015-2020)
Figure 11. Adrenoleukodystrophy Drugs Consumed in Childhood Cerebral ALD
Figure 12. Global Adrenoleukodystrophy Drugs Market: Childhood Cerebral ALD (2015-2020) (K Units)
Figure 13. Global Adrenoleukodystrophy Drugs Market: Childhood Cerebral ALD (2015-2020) ($ Millions)
Figure 14. Adrenoleukodystrophy Drugs Consumed in Adrenomyeloneuropathy (AMN)
Figure 15. Global Adrenoleukodystrophy Drugs Market: Adrenomyeloneuropathy (AMN) (2015-2020) (K Units)
Figure 16. Global Adrenoleukodystrophy Drugs Market: Adrenomyeloneuropathy (AMN) (2015-2020) ($ Millions)
Figure 17. Adrenoleukodystrophy Drugs Consumed in Addison-only
Figure 18. Global Adrenoleukodystrophy Drugs Market: Addison-only (2015-2020) (K Units)
Figure 19. Global Adrenoleukodystrophy Drugs Market: Addison-only (2015-2020) ($ Millions)
Figure 20. Adrenoleukodystrophy Drugs Consumed in Others
Figure 21. Global Adrenoleukodystrophy Drugs Market: Others (2015-2020) (K Units)
Figure 22. Global Adrenoleukodystrophy Drugs Market: Others (2015-2020) ($ Millions)
Figure 23. Global Adrenoleukodystrophy Drugs Consumption Market Share by Application (2015-2020)
Figure 24. Global Adrenoleukodystrophy Drugs Value Market Share by Application (2015-2020)
Figure 25. Global Adrenoleukodystrophy Drugs Sales Market Share by Company in 2017
Figure 26. Global Adrenoleukodystrophy Drugs Sales Market Share by Company in 2019
Figure 27. Global Adrenoleukodystrophy Drugs Revenue Market Share by Company in 2017
Figure 28. Global Adrenoleukodystrophy Drugs Revenue Market Share by Company in 2019
Figure 29. Global Adrenoleukodystrophy Drugs Sale Price by Company in 2019
Figure 30. Global Adrenoleukodystrophy Drugs Consumption Market Share by Regions 2015-2020
Figure 31. Global Adrenoleukodystrophy Drugs Value Market Share by Regions 2015-2020
Figure 32. Americas Adrenoleukodystrophy Drugs Consumption 2015-2020 (K Units)
Figure 33. Americas Adrenoleukodystrophy Drugs Value 2015-2020 ($ Millions)
Figure 34. APAC Adrenoleukodystrophy Drugs Consumption 2015-2020 (K Units)
Figure 35. APAC Adrenoleukodystrophy Drugs Value 2015-2020 ($ Millions)
Figure 36. Europe Adrenoleukodystrophy Drugs Consumption 2015-2020 (K Units)
Figure 37. Europe Adrenoleukodystrophy Drugs Value 2015-2020 ($ Millions)
Figure 38. Middle East & Africa Adrenoleukodystrophy Drugs Consumption 2015-2020 (K Units)
Figure 39. Middle East & Africa Adrenoleukodystrophy Drugs Value 2015-2020 ($ Millions)
Figure 40. Americas Adrenoleukodystrophy Drugs Consumption Market Share by Countries in 2019
Figure 41. Americas Adrenoleukodystrophy Drugs Value Market Share by Countries in 2019
Figure 42. Americas Adrenoleukodystrophy Drugs Consumption Market Share by Type in 2019
Figure 43. Americas Adrenoleukodystrophy Drugs Consumption Market Share by Application in 2019
Figure 44. United States Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 45. United States Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. Canada Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 47. Canada Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 48. Mexico Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 49. Mexico Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 50. APAC Adrenoleukodystrophy Drugs Consumption Market Share by Countries in 2019
Figure 51. APAC Adrenoleukodystrophy Drugs Value Market Share by Regions in 2019
Figure 52. APAC Adrenoleukodystrophy Drugs Consumption Market Share by Type in 2019
Figure 53. APAC Adrenoleukodystrophy Drugs Consumption Market Share by Application in 2019
Figure 54. China Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. China Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Japan Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Japan Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. Korea Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 59. Korea Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. Southeast Asia Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 61. Southeast Asia Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. India Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 63. India Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 64. Australia Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 65. Australia Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 66. Europe Adrenoleukodystrophy Drugs Consumption Market Share by Countries in 2019
Figure 67. Europe Adrenoleukodystrophy Drugs Value Market Share by Countries in 2019
Figure 68. Europe Adrenoleukodystrophy Drugs Consumption Market Share by Type in 2019
Figure 69. Europe Adrenoleukodystrophy Drugs Consumption Market Share by Application in 2019
Figure 70. Germany Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. Germany Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. France Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. France Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. UK Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 75. UK Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Italy Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 77. Italy Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 78. Russia Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 79. Russia Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 80. Middle East & Africa Adrenoleukodystrophy Drugs Consumption Market Share by Countries in 2019
Figure 81. Middle East & Africa Adrenoleukodystrophy Drugs Value Market Share by Countries in 2019
Figure 82. Middle East & Africa Adrenoleukodystrophy Drugs Consumption Market Share by Type in 2019
Figure 83. Middle East & Africa Adrenoleukodystrophy Drugs Consumption Market Share by Application in 2019
Figure 84. Egypt Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. Egypt Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. South Africa Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. South Africa Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. Israel Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 89. Israel Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. Turkey Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 91. Turkey Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 92. GCC Countries Adrenoleukodystrophy Drugs Consumption Growth 2015-2020 (K Units)
Figure 93. GCC Countries Adrenoleukodystrophy Drugs Value Growth 2015-2020 ($ Millions)
Figure 94. Global Adrenoleukodystrophy Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 95. Global Adrenoleukodystrophy Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 96. Americas Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 97. Americas Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 98. APAC Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 99. APAC Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 100. Europe Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 101. Europe Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 102. Middle East & Africa Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 103. Middle East & Africa Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 104. United States Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 105. United States Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 106. Canada Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 107. Canada Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 108. Mexico Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 109. Mexico Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 110. Brazil Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 111. Brazil Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 112. China Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 113. China Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 114. Japan Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 115. Japan Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 116. Korea Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 117. Korea Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 118. Southeast Asia Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 119. Southeast Asia Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 120. India Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 121. India Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 122. Australia Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 123. Australia Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 124. Germany Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 125. Germany Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 126. France Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 127. France Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 128. UK Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 129. UK Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 130. Italy Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 131. Italy Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 132. Russia Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 133. Russia Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 134. Spain Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 135. Spain Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 136. Egypt Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 137. Egypt Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 138. South Africa Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 139. South Africa Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 140. Israel Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 141. Israel Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 142. Turkey Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 143. Turkey Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 144. GCC Countries Adrenoleukodystrophy Drugs Consumption 2021-2025 (K Units)
Figure 145. GCC Countries Adrenoleukodystrophy Drugs Value 2021-2025 ($ Millions)
Figure 146. Bluebird Bio Inc Adrenoleukodystrophy Drugs Market Share (2018-2020)
Figure 147. NeuroVia, Inc. Adrenoleukodystrophy Drugs Market Share (2018-2020)
Figure 148. Minoryx Adrenoleukodystrophy Drugs Market Share (2018-2020)
Figure 149. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Market Share (2018-2020)
Figure 150. Orpheris, Inc. Adrenoleukodystrophy Drugs Market Share (2018-2020)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の副腎白質ジストロフィー薬市場2020-2025:ホルモン補充、移植、その他(Global Adrenoleukodystrophy Drugs Market Growth 2020-2025)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆